Pharmaceutical composition for treating diabetes and its complications and application thereof

A composition and complication technology, applied in the field of medicine, can solve problems such as edema, weight gain, increased insecurity, insulin resistance, etc., and achieve the effect of reducing high blood pressure, reducing the incidence rate, and lowering blood sugar

Active Publication Date: 2012-10-17
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Existing diabetic patients often use insulin supplementation to increase the content of insulin in the body, but long-term use will lead to insulin resistance, while using insulin sensitizers such as pioglitazone alone will cause fluid retention, easy to cause edema and weight gain. increased security

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating diabetes and its complications and application thereof
  • Pharmaceutical composition for treating diabetes and its complications and application thereof
  • Pharmaceutical composition for treating diabetes and its complications and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1 Compound pioglitazone bromocriptine tablet

[0044]

[0045] Preparation process: Weigh the bromocriptine, pioglitazone, starch, dextrin and low-substituted hydroxypropyl cellulose in the prescribed amount and mix them evenly. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 2

[0046] Embodiment 2 Compound pioglitazone bromocriptine tablet

[0047]

[0048] Preparation process: Weigh the prescribed amount of bromocriptine, pioglitazone, microcrystalline cellulose and hydroxypropyl cellulose and mix evenly. Take another appropriate amount of 8% starch slurry solution, add it to the mixed powder, mix evenly to make a soft material, pass through a 16-mesh sieve to granulate, and dry below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

Embodiment 3

[0049] Embodiment 3 compound pioglitazone bromocriptine tablet

[0050]

[0051] Preparation process: Weigh the bromocriptine, pioglitazone, starch, dextrin and low-substituted hydroxypropyl cellulose in the prescribed amount and mix them evenly. Another appropriate amount of 60% ethanol is added to the mixed powder, mixed evenly to make a soft material, granulated through a 16-mesh sieve, and dried below 60°C. After the drying is completed, use an 18-mesh sieve to carry out granulation, sieve out the fine powder in the dry granules, mix with the sieved magnesium stearate, and then mix with the dry granules evenly, and press into tablets to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a pharmaceutical composition for treating or preventing diabetes or its complications and an application thereof, and belongs to the medical field. According to the pharmaceutical composition, an insulin sensitizer and bromocriptine or its medicinal salt are used as active pharmaceutical ingredients. When the pharmaceutical composition is used to treat or prevent diabetes or its complications, the medical action modes are complementary. Therefore, the pharmaceutical composition shows remarkable synergism in the hypoglycemic aspect, has low adverse reaction, requires a low price and has a good application prospect.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition for treating diabetes and its complications and its application, in particular to a pharmaceutical composition containing bromocriptine mesylate or a pharmaceutically acceptable salt thereof and an insulin sensitizer and its application. Use in the preparation of medicines for treating diabetes and its complications. Background technique [0002] Diabetes mellitus (DM) is a group of syndromes caused by environmental and genetic factors. Its basic pathological features are absolute or relative insufficiency of insulin secretion, or peripheral tissue insensitivity to insulin, mainly causing glucose metabolism disorders. A systemic disease involving disorders of fat and protein metabolism. Diabetes Control and Complications Clinical Trial (DCCT), UK Prospective Diabetes Study (UKPDS) and many other evidence-based medical studies have reached a consen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/48A61P3/10A61K31/4439
Inventor 赵志全高雷王洪臣
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap